Isturisa denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for isturisa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Isturisa as Duplicate Therapy

Cigna's duplicate-therapy denial means the plan has identified another medication in your current regimen that it considers to treat the same condition through a substantially similar mechanism. For Isturisa (osilodrostat), which is used to manage Cushing's disease by reducing excess cortisol production, this denial most often arises when a patient is already approved for or dispensing another steroidogenesis inhibitor targeting cortisol synthesis.

This type of denial is routinely appealable because Cushing's disease is a complex endocrine disorder where the clinical rationale for a specific agent — or for combining agents — is highly individualized. Prescribers often have documented clinical reasons why one agent alone is insufficient or why a transition is warranted.

## Federal Appeal Framework

You have layered federal rights regardless of whether your plan is insured or self-funded:

• ACA §2719 / ERISA §503: Entitles you to a full-and-fair internal appeal with a written decision.
• External review: If the internal appeal is denied, you may escalate to an independent review organization (IRO). You generally have approximately four months from the denial notice to file for external review — confirm your exact deadline on the denial letter.
• Expedited review: If your condition is urgent or your health is at serious risk, you may request an expedited internal and external review, often decided within days.

## Concrete Appeal Process and Timeline

1. Submit a written internal appeal to Cigna within the timeframe printed on your Explanation of Benefits (EOB) or denial letter — typically 180 days. 2. Cigna must respond to a standard internal appeal within 30 days (prospective) or 60 days (post-service). 3. If denied internally, file for external review with Cigna's designated IRO within your deadline. 4. Receive an IRO binding decision, typically within 45 days (standard) or 72 hours (expedited).

## Documentation to Gather

• Diagnosis confirmation: Endocrinology records confirming Cushing's disease diagnosis and biochemical workup.
• Treatment history with dates and outcomes: A timeline of all prior cortisol-lowering or pituitary-directed therapies tried, including why each was stopped or was insufficient — documented in chart notes, not just a letter.
• Clinical severity: Recent hormone-level trends, signs and symptoms of active hypercortisolism, and functional-status documentation in the medical record.
• Prescriber medical-necessity letter: A detailed letter from the endocrinologist explaining why Isturisa is clinically distinct from any concurrent or prior agent — different mechanism, different tolerability profile, or inadequate disease control with the other agent.

## Criteria-Mapping Structure

Pull the exact duplicate-therapy language from Cigna's published coverage policy for Isturisa. Then, for every criterion listed:

| Policy Requirement | Documented Chart Evidence | |---|---| | Active diagnosis of Cushing's disease | [Date of confirmed diagnosis, source] | | Prior agent tried or contraindicated | [Agent, dates, outcome per chart] | | Clinical rationale for Isturisa over or alongside the prior agent | [Prescriber's documented reasoning] |

Submit this mapping with every cited record attached. Reviewers approve appeals faster when the evidence is organized to mirror each policy criterion rather than submitted as a general narrative.